Qudsia Hussain, MD
Endocrinology, Diabetes & Metabolism · Washington, DCNPI 1013448638
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 376 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 38 manufacturers reported payments, led by Lilly USA, LLC at 28.2% of the total. Reporting peaked in 2024 at $3,815 and has fallen 80.9% since, to $728 in 2025.
Across 376 payments — averaging $24.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$3K
- Cequr Corporation$738
- Novo Nordisk$720
- Amneal Pharmaceuticals LLC$707
- Boehringer Ingelheim$417
- Mannkind Corporation$354
- plus $4K from 32 others
What the payments were for
- Food & beverage$9,314100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 107 | $2,629 |
| Cequr Corporation | 4 | $738 |
| Novo Nordisk | 33 | $720 |
| Amneal Pharmaceuticals LLC | 32 | $707 |
| Boehringer Ingelheim | 21 | $417 |
| Mannkind Corporation | 16 | $354 |
| Insulet Corporation | 6 | $336 |
| Sanofi-aventis U.S. LLC | 17 | $335 |
| Amgen(2 entities) | 16 | $335 |
| AstraZeneca(2 entities) | 15 | $296 |
| Xeris Pharmaceuticals, Inc. | 14 | $286 |
| Corcept Therapeutics | 12 | $283 |
| Abbott | 12 | $236 |
| Tandem Diabetes Care, Inc. | 7 | $232 |
| Antares Pharma, Inc. | 10 | $204 |
| Radius Health, Inc. | 13 | $193 |
| Ascensia Diabetes Care US Inc. | 2 | $123 |
| Halozyme Inc | 4 | $96 |
| Novartis | 4 | $88 |
| AbbVie | 4 | $85 |
| Dexcom, Inc. | 2 | $59 |
| Recordati_rare_diseases_inc. | 3 | $57 |
| Nevro Corp. | 2 | $55 |
| Amphastar Pharmaceuticals, Inc. | 2 | $48 |
| Embecta Corp. | 1 | $43 |
| Ascendis Pharma Endocrinology Inc | 2 | $41 |
| IBSA Pharma Inc. | 2 | $39 |
| Esperion Therapeutics, Inc. | 2 | $38 |
| Medtronic | 1 | $33 |
| Tolmar, Inc. | 2 | $32 |
| Lifescan, Inc. | 1 | $28 |
| Pfizer | 1 | $26 |
| Envista Holdings Corporation | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Neurocrine Biosciences, Inc. | 1 | $22 |
| Bayer | 1 | $21 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| BETA Bionics, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$572
- Omnipod$238
How this compares
$9,314 in reported general payments places this provider in the 80th percentile of 44 endocrinology, diabetes & metabolism providers in District of Columbia.
See all endocrinology, diabetes & metabolism providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 160 | $287,988 |
| TrulicityDulaglutide | 134 | $255,580 |
| JardianceEmpagliflozin | 77 | $109,534 |
| OzempicSemaglutide | 46 | $94,643 |
| Tresiba Flextouch U-100Insulin Degludec | 81 | $62,167 |
| FarxigaDapagliflozin Propanediol | 36 | $53,543 |
| JanuviaSitagliptin Phosphate | 35 | $49,665 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 18 | $31,749 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $19,195 |
| Gvoke Hypopen 2-PackGlucagon | 13 | $7,921 |
| Humalog Kwikpen U-100Insulin Lispro | 34 | $6,953 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 53 | $6,907 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 41 | $6,557 |
| SynthroidLevothyroxine Sodium | 53 | $4,994 |
| Insulin Lispro Kwikpen U-100Insulin Lispro | 11 | $4,806 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $2,629 | $543,567294 claims |
| Boehringer IngelheimJardiance, Synjardy Xr | $417 | $141,28395 claims |
| Novo NordiskOzempic | $720 | $94,64346 claims |
| AstraZenecaFarxiga | $296 | $53,54336 claims |
| AbbVieSynthroid | $85 | $4,99453 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $707 | $1,932197 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 44 endocrinology, diabetes & metabolism providers in District of Columbia.
Other endocrinology, diabetes & metabolism in Washington
- Natasa Janicic-KahricWashington$121K
- Diala El-MaoucheWashington$99K
- Abbas MotazediWashington$31K
- Meeta SharmaWashington$25K
- Joseph VerbalisWashington$24K
- Mark SklarWashington$14K
- Sabyasachi SenWashington$12K
- Rui LuWashington$12K
- Jerold ShareWashington$7K
- Leonard WartofskyWashington$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.